EC
TVTX icon

Elequin Capital’s Travere Therapeutics TVTX Stock Holding History

Elequin Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862 Sell
29
-78
-73% -$2.33K ﹤0.01% 550
2025
Q4 		$4.09K Buy
+107
New +$3.48K ﹤0.01% 317
2025
Q3 		– Sell
-50
Closed -$740 – 384
2025
Q2 		$740 Buy
+50
New +$829 ﹤0.01% 344
2024
Q4 		– Sell
-462
Closed -$6.46K – 635
2024
Q3 		$6.46K Buy
+462
New +$4.81K ﹤0.01% 275
2024
Q2 		– Sell
-1,430
Closed -$11K – 353
2024
Q1 		$11K Buy
1,430
+1,410
+7,050% +$11.9K ﹤0.01% 90
2023
Q4 		$180 Sell
20
-6
-23% -$44 ﹤0.01% 337
2023
Q3 		$232 Sell
26
-504
-95% -$7.11K ﹤0.01% 362
2023
Q2 		$8.14K Buy
+530
New +$9.64K ﹤0.01% 326
2023
Q1 		– Sell
-7,088
Closed -$149K – 523
2022
Q4 		$149K Buy
+7,088
New +$150K 0.04% 215
2022
Q3 		– Sell
-388
Closed -$9K – 676
2022
Q2 		$9K Buy
388
+354
+1,041% +$8.9K ﹤0.01% 252
2022
Q1 		$1K Buy
+34
New +$903 ﹤0.01% 303

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Elequin Capital's TVTX Position: Q1 2026 in Review

Elequin Capital reduced its Travere Therapeutics (TVTX) stake by 73% in Q1 2026, selling an estimated $2.33K and leaving 29 shares worth $862. The position accounts for ﹤0.01% of the portfolio, ranked #550.

Elequin Capital first reported a position in TVTX in Q1 2022 and has held it in 11 quarters since. The position peaked at $149K in Q4 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Elequin Capital held 29 shares of Travere Therapeutics worth $862 as of Q1 2026.
  • Elequin Capital sold 78 Travere Therapeutics shares in Q1 2026, an estimated $2.33K.
  • Travere Therapeutics made up ﹤0.01% of Elequin Capital's portfolio in Q1 2026, its #550 holding.
  • Elequin Capital first reported a position in Travere Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Elequin Capital's Travere Therapeutics position peaked at $149K in Q4 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.